Two-year outcomes of high bleeding risk patients with acute coronary syndrome after Biolimus A9 polymer-free drug-coated stents: a LEADERS FREE substudy

EuroIntervention. 2018 Mar 20;13(16):1946-1949. doi: 10.4244/EIJ-D-17-00720.

Authors

Christoph J Jensen¹, Christoph K Naber, Philip Urban, Paul J Ong, Mariano Valdes-Chavarri, Alexandre A Abizaid, Stuart J Pocock, Franco Fabbiocchi, Christophe Dubois, Samuel Copt, Hans-Peter Stoll, Marie-Claude Morice

Affiliation

¹ Contilia Heart and Vascular Centre, Elisabeth Krankenhaus Essen, Essen, Germany.

PMID: 29336310
DOI: 10.4244/EIJ-D-17-00720

No abstract available

Publication types

Randomized Controlled Trial

MeSH terms

Acute Coronary Syndrome / blood
Acute Coronary Syndrome / diagnostic imaging
Acute Coronary Syndrome / mortality
Acute Coronary Syndrome / surgery*
Cardiovascular Agents / administration & dosage*
Cardiovascular Agents / adverse effects
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Drug-Eluting Stents*
Hemorrhage / chemically induced*
Hemorrhage / mortality
Humans
Percutaneous Coronary Intervention / adverse effects*
Percutaneous Coronary Intervention / instrumentation*
Percutaneous Coronary Intervention / mortality
Platelet Aggregation Inhibitors / administration & dosage*
Platelet Aggregation Inhibitors / adverse effects
Prosthesis Design
Risk Assessment
Risk Factors
Sirolimus / administration & dosage
Sirolimus / adverse effects
Sirolimus / analogs & derivatives*
Time Factors
Treatment Outcome

Substances

Cardiovascular Agents
Platelet Aggregation Inhibitors
umirolimus
Sirolimus